Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

Yuqin Song, Luis Malpica, Qingqing Cai, Weili Zhao, Keshu Zhou, Jianqiu Wu, Huilai Zhang, Neha Mehta-Shah, Kaiyang Ding, Yao Liu, Zengjun Li, Liling Zhang, Meifang Zheng, Jie Jin, Haiyan Yang, Yuerong Shuang, Dok Hyun Yoon, Sujun Gao, Wenyu Li, Zhimin ZhaiLiqun Zou, Yaming Xi, Youngil Koh, Fei Li, Miles Prince, Hui Zhou, Lie Lin, Hui Liu, Pamela Allen, Fernando Roncolato, Zhenfan Yang, Won Seog Kim, Jun Zhu

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences